Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.
COVID recovery
COVID-19
COVID-19 symptoms
Long COVID
Long Hauler
PASC
Patient-Led research
Post Acute COVID
Post-COVID-19 Syndrome
Post-acute Sequelae of COVID-19
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
02
04
2021
revised:
18
06
2021
accepted:
21
06
2021
pubmed:
27
7
2021
medline:
27
7
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
A significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this population, particularly in outpatient settings. Hence, relatively little is known about symptom makeup and severity, expected clinical course, impact on daily functioning, and return to baseline health. We conducted an online survey of people with suspected and confirmed COVID-19, distributed via COVID-19 support groups (e.g. Body Politic, Long COVID Support Group, Long Haul COVID Fighters) and social media (e.g. Twitter, Facebook). Data were collected from September 6, 2020 to November 25, 2020. We analyzed responses from 3762 participants with confirmed (diagnostic/antibody positive; 1020) or suspected (diagnostic/antibody negative or untested; 2742) COVID-19, from 56 countries, with illness lasting over 28 days and onset prior to June 2020. We estimated the prevalence of 203 symptoms in 10 organ systems and traced 66 symptoms over seven months. We measured the impact on life, work, and return to baseline health. For the majority of respondents (>91%), the time to recovery exceeded 35 weeks. During their illness, participants experienced an average of 55.9+/- 25.5 (mean+/-STD) symptoms, across an average of 9.1 organ systems. The most frequent symptoms after month 6 were fatigue, post-exertional malaise, and cognitive dysfunction. Symptoms varied in their prevalence over time, and we identified three symptom clusters, each with a characteristic temporal profile. 85.9% of participants (95% CI, 84.8% to 87.0%) experienced relapses, primarily triggered by exercise, physical or mental activity, and stress. 86.7% (85.6% to 92.5%) of unrecovered respondents were experiencing fatigue at the time of survey, compared to 44.7% (38.5% to 50.5%) of recovered respondents. 1700 respondents (45.2%) required a reduced work schedule compared to pre-illness, and an additional 839 (22.3%) were not working at the time of survey due to illness. Cognitive dysfunction or memory issues were common across all age groups (~88%). Except for loss of smell and taste, the prevalence and trajectory of all symptoms were similar between groups with confirmed and suspected COVID-19. Patients with Long COVID report prolonged, multisystem involvement and significant disability. By seven months, many patients have not yet recovered (mainly from systemic and neurological/cognitive symptoms), have not returned to previous levels of work, and continue to experience significant symptom burden. All authors contributed to this work in a voluntary capacity. The cost of survey hosting (on Qualtrics) and publication fee was covered by AA's research grant (Wellcome Trust/Gatsby Charity via Sainsbury Wellcome center, UCL).
Sections du résumé
BACKGROUND
BACKGROUND
A significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this population, particularly in outpatient settings. Hence, relatively little is known about symptom makeup and severity, expected clinical course, impact on daily functioning, and return to baseline health.
METHODS
METHODS
We conducted an online survey of people with suspected and confirmed COVID-19, distributed via COVID-19 support groups (e.g. Body Politic, Long COVID Support Group, Long Haul COVID Fighters) and social media (e.g. Twitter, Facebook). Data were collected from September 6, 2020 to November 25, 2020. We analyzed responses from 3762 participants with confirmed (diagnostic/antibody positive; 1020) or suspected (diagnostic/antibody negative or untested; 2742) COVID-19, from 56 countries, with illness lasting over 28 days and onset prior to June 2020. We estimated the prevalence of 203 symptoms in 10 organ systems and traced 66 symptoms over seven months. We measured the impact on life, work, and return to baseline health.
FINDINGS
RESULTS
For the majority of respondents (>91%), the time to recovery exceeded 35 weeks. During their illness, participants experienced an average of 55.9+/- 25.5 (mean+/-STD) symptoms, across an average of 9.1 organ systems. The most frequent symptoms after month 6 were fatigue, post-exertional malaise, and cognitive dysfunction. Symptoms varied in their prevalence over time, and we identified three symptom clusters, each with a characteristic temporal profile. 85.9% of participants (95% CI, 84.8% to 87.0%) experienced relapses, primarily triggered by exercise, physical or mental activity, and stress. 86.7% (85.6% to 92.5%) of unrecovered respondents were experiencing fatigue at the time of survey, compared to 44.7% (38.5% to 50.5%) of recovered respondents. 1700 respondents (45.2%) required a reduced work schedule compared to pre-illness, and an additional 839 (22.3%) were not working at the time of survey due to illness. Cognitive dysfunction or memory issues were common across all age groups (~88%). Except for loss of smell and taste, the prevalence and trajectory of all symptoms were similar between groups with confirmed and suspected COVID-19.
INTERPRETATION
CONCLUSIONS
Patients with Long COVID report prolonged, multisystem involvement and significant disability. By seven months, many patients have not yet recovered (mainly from systemic and neurological/cognitive symptoms), have not returned to previous levels of work, and continue to experience significant symptom burden.
FUNDING
BACKGROUND
All authors contributed to this work in a voluntary capacity. The cost of survey hosting (on Qualtrics) and publication fee was covered by AA's research grant (Wellcome Trust/Gatsby Charity via Sainsbury Wellcome center, UCL).
Identifiants
pubmed: 34308300
doi: 10.1016/j.eclinm.2021.101019
pii: S2589-5370(21)00299-6
pmc: PMC8280690
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101019Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
All authors have completed the ICMJE uniform disclosure form and declare: no support from any organization for the submitted work. All authors except HED and GSA declare no financial relationships with any organization that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. HED reports personal fees ($500 speaking fee) from Council for Medical Specialty Society, outside the submitted work. GSA reports personal fees ($1000 speaking fee) from Council for Medical Specialty Society and Karolinska Institute, outside the submitted work.
Références
JAMA. 2020 Apr 21;323(15):1437-1438
pubmed: 32150622
EClinicalMedicine. 2021 Sep;39:101044
pubmed: 34316551
JAMA Netw Open. 2021 Feb 1;4(2):e210337
pubmed: 33576815
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
PLoS One. 2020 Dec 10;15(12):e0242958
pubmed: 33301459
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
Front Neurol. 2020 Sep 18;11:1025
pubmed: 33071931
Int J Infect Dis. 2020 Nov;100:327-332
pubmed: 32920235
Clin Infect Dis. 2021 Dec 6;73(11):e4058-e4063
pubmed: 33252665
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
Br J Health Psychol. 2004 Sep;9(Pt 3):279-91
pubmed: 15296678
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Lancet. 2020 Sep 5;396(10252):e24
pubmed: 32861312
Emerg Microbes Infect. 2020 Dec;9(1):1175-1179
pubmed: 32448084
Soc Sci Med. 2021 Jan;268:113426
pubmed: 33199035
J Infect. 2021 Feb;82(2):e1-e4
pubmed: 33285216
Heart Rhythm. 2020 Nov;17(11):1984-1990
pubmed: 32599178
Emerg Infect Dis. 2020 Jun;26(6):1337-1339
pubmed: 32150527
J Clin Med. 2020 Sep 12;9(9):
pubmed: 32932582
Pain Rep. 2021 Apr 13;6(1):e913
pubmed: 33987484
MedComm (2020). 2020 Jul 02;1(2):253-256
pubmed: 34172986
Cureus. 2018 Apr 5;10(4):e2435
pubmed: 29876157
BMJ. 2020 May 12;369:m1808
pubmed: 32398230
JAMA. 2021 Jan 12;325(2):122
pubmed: 33433583
Postgrad Med J. 2007 Jul;83(981):478-80
pubmed: 17621618
Nature. 2021 Jun;594(7862):259-264
pubmed: 33887749
BMC Health Serv Res. 2020 Dec 20;20(1):1144
pubmed: 33342437
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026